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Definition of stroke, epidemiology and role of genetic in the different subtypes 
The World Health Organization defines stroke as rapidly developing signs of focal disturbance 
of cerebral function with symptoms lasting at least 24 hours or leading to death with no 
apparent cause other than of vascular origin (WHO Project, 1998). This definition is far from 
ideal for children, because children with symptoms compatible with transient ischemic attack 
can have brain infarction shown by brain imaging despite the transient nature of their 
symptoms. Consequently, pediatric stroke is defined as any neurological event (including a 
seizure) associated with an acute infarction shown by magnetic resonance imaging. (Seidman 
C, 2007) 
Stroke can be ischemic, hemorrhagic, or both. Ischemic stroke is more frequently caused by 
arterial occlusion, but it may also be caused by venous occlusion of cerebral veins or sinuses.  
Stroke has been considered a rare event in neonates and children, with a reported incidence of 
combined ischemic and hemorrhagic pediatric stroke ranges from 1.2 to 13 cases per 100,000 
children under 18 years of age (Tszee D.S., 2011; Carvalho KS, 2002; deVeber GA, 2017; 
Suppiej A, 2015). The overall incidence is increasing due to a combination of improved 
survival of those with risk factors and increased recognition. (Nikil K. Rajani, 2018) 
In perinatal period, between 20 week of gestational age and 28 days of postnatal life, the 
incidence appears to be 17-times higher (Sebastian Grunt, May 2015; Janet Lee, February 9, 
2005). However, both perinatal and pediatric stroke is likely more common than we may 
realize since it is frequently undiagnosed or misdiagnosed (Nidhi Agrawal, 2009; Malova M, 
2017 Jan; Parodi A, 2015 Nov).  
 
 
Cerebral sinovenous thrombosis (CSVT) is a rare but serious cerebrovascular 
disorder-affecting children from the newborn period through childhood and adolescence. The 
incidence is estimated at 0.6/100,000/year, with 30–50% occurring in newborns. Causes are 
diverse and are highly age-dependent. Acute systemic illness is the dominant risk factor among 
newborns. In childhood CSVT, acute infections of the head and neck such as mastoiditis are the 
most common, followed by chronic underlying diseases such as nephrotic syndrome, cancer 
(i.e. or asparaginase administration during treatment for leukemia or lymphoma), and 
inflammatory bowel disease (Ichord RN, 2015). 
A significant proportion of cases (∼13–25percentage) have no risk factors identified suggesting 
that undetermined genetic factors may at least partly account for this unexplained risk. 
Although it is a rare condition, it does not usually cluster in families and there is no evidence to 
suggest a Mendelian inheritance. Neither the genetic component of CSVT nor its heritability 
has been widely assessed mainly because of its low incidence and lack of large number of 
cases. (Cotlarciuc I, 2016). Inherited thrombophilias are known to cause approximately a 
quarter of the CSVT cases in adulthood (Ahmad A, 2006), while in pediatric and neonatal age 
the prevalence of hereditary thrombophilias varies significantly from study to study (from 20 to 
64%) probably due to different populations studied (Se´bire G, 2005; Dlaminia N, 2010). 
 
Hemorrhagic stroke (HS) is the result of bleeding from a ruptured cerebral artery or, in 
some cases, from bleeding into the site of an acute ischemic stroke. Intracerebral hemorrhage 
(ICH) may be either traumatic or non-traumatic (spontaneous ICH).  
The reported incidence of asymptomatic and symptomatic ICH in children varies from study to 
study probably due to differences in the sensitivity and timing of the diagnostic imaging used 
(Zidan I, 2012; May Llanas M.E., 1999). 
In the neonatal population, the incidence of HS was more investigated; a magnetic resonance 
imaging (MRI) study of full-term neonates found approximately a 25% incidence of 
asymptomatic intracranial hemorrhage after vaginal delivery (Looney CB, 2007). Symptomatic 
intracranial hemorrhage in full-term neonates is much less common, in the range of 4 per 
10,000 live births. The incidence is higher, however, in instrumented births (Towner D, 1999). 
Most non-traumatic hemorrhagic strokes may originate in or extend into the intraventricular, 
subdural, or subarachnoid space. (Pavlakis, 2008; Gabis L. V., 2002) 
Studies about children with HS show that first cause is vascular malformations, which are 
responsible of 5%–29% of cerebral hemorrhages, whereas other causes are hematological 
disorders, such as thrombocytopenia or hemophilia, and malignancies. (Gabis L. V., 2002; 
Pavlakis, 2008) 
The most common vascular malformations are arteriovenous malformations (AVMs), 
aneurysms, and cavernous malformations. Aneurysms and hypertension, although commonly 
associated with adult HS, are an infrequent cause in children. (Lynch J.K., 2005) 
AVMs account for 14% to 46% of HS in children (Zidan I, 2012). Most AVMs are diagnosed 
in patients between 20 and 40 years, but about 18% to 20% will become symptomatic during 
childhood. 
The incidence of intracranial aneurysms in children is about 1 per million per year, 
substantially less than the adult rate. About 1% to 2% of aneurysms will become symptomatic 
in childhood, mainly with HS. (Gabis L. V., 2002) 
Hematologic abnormalities are reported to be the major risk factor in 10% to 32% of 
hemorrhagic strokes in most series (A. Al-Jarallah, 2000; Meyer-Heim A.D, 2003). Those 
includes idiopathic thrombocytopenic purpura, acute lymphoblastic anemia, sickle cell anemia, 
moderate and severe hemophilia A and B, and other coagulopathies (such as severe Factor XIII 
deficiency) (Briggs B, 2018). Brain tumors are also found to be one of the causes of ICH in 
children with a much lower incidence than previously mentioned causes. Anticoagulant 
treatment, largely in relationship to warfarin use, has also been consistently associated with HS 
risk in adulthood, while in pediatric setting the role of this risk factor appears to be a minority. 
(Guido J. Falcone, 2017).  
Mendelian forms of ICH represent only a small fraction of the total number of cases 
(∼5percentage of hemorrhagic strokes being caused by genetic coagulopathies, some others by 
COL4A1-related diseases) (Guido J. Falcone, 2017; Benjamin Briggs, 2018) 
 
Arterial ischemic stroke (AIS) accounts for about half of all strokes in children, in 
contrast to neonate and adults in whom 80–85% of all strokes are ischemic. This population has 





Epidemiology of Arterial Ischemic Stroke in Children, Clinical Presentation 
and outcome 
Population-based studies of arterial ischemic stroke (AIS) in children (defined by age 29 days 
to 18 years) estimate an annual incidence of 2.4 per 100,000. (Numis A.L., 2014) 
Whilst stroke classically presents with an acute focal neurological deficit such as hemiplegia, 
speech or gait disturbance, the presentation is highly dependent on the age of the child and may 
not be specific. Toddlers and infants tend to present most non-specifically, with features such 
as irritability, somnolence, lethargy, feeding difficulty, apnea and hypotonia. (Nikil K. Rajani, 
2018). Approximately 30–50% of children with an acute neurological presentation will have 
non-vascular diagnoses (Mackay M, 2014). The clinical onset depends also on the involved 
vascular territory (Figure 1). 
Figure 1. Onset symptoms in relation to involved vascular territory. 
 
 
AIS can lead to significant morbidity and mortality and, contrary to commonly held 
views, children do not recover better than adults do after a stroke (Greenham M, 2016). 
Roughly,10–25% of children with a stroke will die in the first years after stroke, with a stroke-
specific mortality around 5% (deVeber GA, 2017; Daniel S. Tszee, 2011).  
Outcomes included neurological deficits in 60% of neonates and 70% of older children. Among 
neonates, deficits emerged during follow-up in around 40% (deVeber GA, 2017). Other 
sequelae includes subsequent seizure disorders, learning, or developmental problems (Daniel S. 
Tszee, 2011; Greenham M, 2016). 
Recurrence risk after childhood AIS has been estimated at 12% at one year and 19% at five 
years (Fullerton, 2007). 
 
AIS Risk factors and predictor of recurrency 
A heterogeneous group of risk factors has been identified in association with childhood AIS. 
Remarkably, those risk factors are different from those found in adults. Indeed, the most 
frequent causes of childhood AIS are acute systemic disorders (e.e. sepsis, deyhidratation, 
acidosis) and non-atherosclerotic arteriopathies, such as focal cerebral arteriopathy, fibro-
muscular dysplasia, and Moya-Moya syndrome, followed by congenital or acquired heart 
diseases, hemoglobinopathies (such as sickle cell disease - SCD), trauma, major prothrombotic 
states (Felling RJ, 2017; Nikil K. Rajani, 2018) (Mackay MT W. M., 2011).  
The main risk factors for pediatric AIS are summarized in Table 1 
Table 1. Main risk factors for pediatric AIS 
Arteriopathy  53%   
 FCA   
 Moyamoya Idiopathic  
  RNF213 gene 17q25.   
  ACTA2 gene 10q23.3   
  GUCY1A3 gene 4q32.   
  Down Syndrome   
   NF1  
 Dissection Extracranial/traumatic   
  Intracranial/spontaneous Idiopathic 
   Ehlers Danlos, Marfan’s 
 Vasculitis Primary Takayasu arteritis  
   Kawasaki Disease 
  Secondary  Infectious  
   Post Varicella Angiophaty 
   immune complex deposition (i.e. SLE) 
Cardiac disorders 31%   
  
 Uncorrected CHD with Complex right-to-left shunting 
 Cardiac surgery, ECMO 
Cardiomyopathy with reduced LVEF 
 
Muscular dystrophy  
   Friedreich’s ataxia 
   Chagas’ disease 
Blood disorders    
 SCD    
 Prothrombotic disorders Protein C deficiency  
   APL syndrome 
   Factor V Leiden 
   Elevated homocysteine 
   Oral Contraceptive 
   Protein S deficiency 
Metabolic causes    
 MELAS   
 Fabry diseases (rare in childhood AIS)  
Other genetic cause*   
FCA = Focal Cerebral arteriopathy; CHD = Cardiac hearth diseases; ECMO = Extracorporeal 
Membrane Oxygenarion ; SCD = sickle cell diseases; APL antiphospholipid;  
* see below. 
Further, many of the risk factors listed in Table 1 may overlap or have a common mechanism. 
This is the case of cerebral arteriopathy, an “umbrella term” used to describe a broad range of 
cause. Cerebral arteriopathy may be the result of both underlying genetic conditions (such as 
NF1, PHACE syndrome or fibromuscular dysplasia), and acquired conditions such as trauma, 
radiation therapy or infection (i.e. VZV or other common viroses), or finally develop in a 
previously healthy child without any other known risk factors. (Nikil K. Rajani, 2018) 
Cerebral arteriopathy is a leading mechanism for childhood stroke, accounting for 53% of 
pediatric AIS cases and represents the most common single cause of stroke recurrence in 
children (Beslow LA, 2010; Fullerton, 2007). Recurrent AIS or transient ischemic attack (TIA) 
in children is predicted also by presentation without seizures, and lack of antithrombotic 
treatment (deVeber GA, 2017). 
 
State of art of genetic in ischemic stroke 
Stroke in childhood is more common than brain tumor, but because there is a wide spectrum in 
terms of etiology and most centers only see a few cases every year, there have been few large 
studies of genetic and environmental risk factors until recently.  
Hopefully, enhanced understanding of the mechanisms underlying childhood stroke, including 
cerebral arteriopathies, will allow the development of mechanism-specific treatment 
approaches and optimize outcome and management in children. (Kirton A, 2015) 
 
Monogenic diseases 
Several rare Mendelian disorders have been described in which stroke is a prominent feature. 
Recognition of individuals and families carrying mutations causing Mendelian diseases with 
stroke as a phenotypic manifestation remains an important challenge for clinicians. Mendelian 
disorders can be recognized mostly when the more common risk factors are lacking  or by their 
familial aggregation, relatively young age of onset, often more severe clinical course, and 
higher recurrence rates, compared with sporadic diseases. (Terni E, 2015) In these cases, the 
diagnosis could be aided by characteristic clinical phenotypes, often including manifestation of 
co-existent systemic disease; however, especially in the case of an early onset cerebrovascular 
disease, stroke may be the first symptom of the genetic disorder. (Bertamino M, 2018) 
Monogenic diseases are responsible of about 5% of stroke cases in young adult patients; 
however, the percentage is likely to be underestimated because of the diagnostic complexity 
and the high phenotypic variability of these conditions. The real incidence in pediatric-onset 
stroke is unknown yet, but certainly significantly higher. 
Stroke can result from one of several pathogenic mechanisms, which might be influenced by a 
single-gene defect. Cardio embolism (i.e. cardiomyopathies, familiar atrial myxoma), small 
arterial diseases (i.e. CADASIL, CARASIL, Fabry’s disease), large artery diseases (i.e. 
Homocysteinuria), hematological disorders (i.e. SCD, Severe prothrombotic states), dissection 
due to connective tissue disorders are the main pathogenic mechanisms reported in children and 
young adult. (Hassan A, 2000) 
Ferro et all in 2010 described more than 50 monogenic diseases that can cause stroke in young 
adults. (Ferro J.M., 2010)  
More recently, Munot et al have drawn attention to the association of childhood AIS with 
Mendelian genetic disorders, thus providing insights into disease pathogenesis, especially when 
non-atherosclerotic arteriopathies are involved. (Munot P, 2011) 
In Mendelian disorders, the presence of a pathogenic mutation(s) of a single specific gene is 
usually sufficient to manifest a phenotype. However, a clear genotype-phenotype correlation is 
very rarely observed in monogenic strokes. At least two genetic phenomenons can influence the 
phenotype in both heterozygosites and homozygotes: the reduced penetrance and a variable 
expressivity, which refers to the type, severity and natural history of the disease. Among the 
factors inducing the variable expressivity, the functional effect of the mutation (complete 
absence of the encoded protein rather than its loss -or gain- of function), the allelic 
heterogeneity (different mutations in the gene), the interaction with other genes (pleiotropy) or 
with the environment are the most documented ones. In X-linked diseases, the clinical 
expression in females is possible, and the severity of the phenotype is caused by the 
phenomenon of X inactivation (‘mosaicism’). (Terni E, 2015) 
 
Environmental exposure (i.e., infection, hypoxemia, and vitamins) may play a crucial role in 
modifying genetic expression and must be carefully described in prospective studies. 
Moreover, the search for polymorphisms with epistatic effects, able to explain why some but 
not all the carriers are affected has been hampered by our poor understanding of the disease 
pathophysiology. (Kirkam FJ, 2003). 
In deep, in cerebrovascular disorders field, advanced vascular imaging, including arteriography 
and Black Blood Vassal Wall (BBVW) imaging technique, will almost certainly assist with the 
description of stroke subtypes with different genetic predisposition in these patients.  
 
 Polygenic conditions 
Several studies on young adults showed how, in most cases, it is likely that multiple genes are 
involved in stroke pathogenesis acting on a wide range of candidate pathways, such as the 
hemostatic and inflammatory system, homocysteine metabolism, and so others. (Terni E, 
2015). Overall, the genetic risk factors for those polygenic forms are less well understood. In 
most of these cases stroke represents a complex condition, where multiple genes and the 
environment are both necessary to reach a threshold level, critical for the phenotype 
manifestation.  
In this scenario, the role of a great number of candidate genes has been investigated through 
association studies, with controversial results. (Agerholm-Larsen B., 1997; Pfohl M., 1998; 
Rigat B., 1990; Cambien F. 1992; Tuncer N. 2006; Casas J.P. 2004) 
The advent of GWAS technology, such as for adult stroke and other complex pathological 
conditions, could contribute enormously to the understanding of the genetic base of many 
stroke events (i.e. idiopathic perinatal stroke). 
Next Generation Sequencing technique 
Next generation sequencing (NGS) is a relatively new technique now being applied to genetic 
testing. NGS has the potential to find causal mutations, including -de novo, novel and familial 
mutations, associated with pediatric and perinatal stroke and, due the variable phenotypic 
presentations of the disorder, vastly improve molecular diagnosis.  
First generation DNA sequencing with chain-terminating inhibitors invented by Sanger in 1977 
(Sanger F., 1977), led to many genetic discoveries and has been widely used for over 30 years 
in research and diagnostic laboratories. Although considered a major technological 
breakthrough, and still useful today for variant verification, the technique has limitations, in 
particular when examining large regions of the genome. More recently, NGS has begun to 
replace Sanger sequencing due to its ability to sequence large numbers of genes, the whole 
exome (protein-coding regions) or entire genome at once. Thus, applications of NGS include 
targeted gene panels, whole exome sequencing (WES) and whole genome sequencing (WGS). 
Custom gene panel testing allows for screening of multiple potentially clinically relevant genes 
and for more flexibility in phenotype–genotype correlations than required when testing 
individual genes. (Poduri A., 2014)  
WES focuses on the protein coding regions in the genome, comprising approximately 1–2% of 
the genome, which ~85% of disease related mutations are attributable to. In contrast, WGS 
provides information on the entire genome (both coding and non-coding regions), detecting 
additional mutations in regulatory regions, as well as copy number variations with higher 
efficiency than WES (Poduri A., 2014; Stavropoulos D. J., 2016). The ~99% of the genome not 
included as exome sequence also contains untranslated regions which may have a regulatory 
role (e.g., non-coding RNAs or transcription binding sites) along with potential protein coding 
sites yet to be annotated as genes. (Chrystoja C. C., 2014) The impact of variants found in non-
coding regions is not currently well understood, however it is feasible that a single or a 
combination of regulatory variants could have a significant impact on the pathology of 
conditions such as stroke. This is most evident for non-coding variants that may influence 
expression levels or mRNA splicing, affecting protein abundance or isoforms. 
Use of NGS technologies in research and diagnostic laboratories has contributed to the rise to 
the rapid identification of genes associated with stroke in young adult but, to date, there are few 
studies on the suitability of the three above mentioned NGS techniques in pediatric and 
perinatal stroke, with a particular focus on their application to aiding clinicians and laboratories 
for a timely genetic stroke diagnosis. 
NEXT GENERATION SEQUENCING BASED GENE PANEL FOR 




Here, we consider insights into the pathogenesis of neonatal and childhood stroke, starting from 
several reports in the literature showing the association between Mendelian diseases and an 
increased risk of early onset stroke (Munot P, 2011).  
Therefore our hypothesis is that pediatric stroke, after the exclusion of more common etiology 
has, in some cases, a simple Mendelian inheritance characterized by genetic heterogeneity so 
that several genes may be responsible of the different clinical forms of the disease.  
Thus, with the present project we aim at studying through Next Generation Sequencing (NGS) 
genetic analysis patients, responding to strictly defined “idiopathic” stroke.  
 
A Next Generation Sequencing strategy is being undertaken to  
1) overcome poor performances of the Sanger sequencing based molecular diagnosis of 
heterogeneous stroke associated syndromes,  
2) avoid clinical misdiagnosis  
3) investigate a large number of genes and gene regions, taking into account genetic 
heterogeneity for patients affected with different diseases sharing cerebral stroke and 
whose genetics is still unknown/undisclosed.  
The present project has been developed inside the multidisciplinary scientific and clinical team 
that have the fortunate possibility to work very closely inside the Giannina Gaslini Children's 
Hospital with the final aim to carefully and according to best practice manage these patients. It 
provides, in an increasing number of cases, the opportunity to patients and physicians to have a 




The primary objective of this study was to analyze the diagnostic yield of next-generation 
sequencing stroke panels in selected subjects with pediatric or perinatal stroke. 
Secondary objective was to perform massive sequencing (WES) of trios (proband and parents) 
in selected cases, negative on the NGS panel, to identify new disorder causing 
single genes leading to ischemic stroke and to study the variant segregation of the 




We enrolled patients referred for diagnostic work-up from 2015 to 2018 to Gaslini Children 
Hospital (Genoa, Italy), who presented with a pediatric or neonatal onset AIS of unknown 
etiology. The study was conducted according to the ethical standards laid down in the 1964 
Declaration of Helsinki and approved by the Internal Review Board.  
Before participation, written informed consent was obtained from all parents or legal guardian. 
Patients up to18 years were considered eligible when presenting one or more of the following 
inclusion criteria: 
i) Single or multiple AIS with cerebral arteriopathy;  
ii) Multiple asynchronous AIS without cerebral arteriopathy; 
iii) Single or multiple AIS with multi-system arteriopathy (with or without cerebral 
arteriopathy) 
iv) Single or multiple porencephaly with AIS and/or  brain calcifications with 
strong family history of AIS in childhood; 
v) Single or multiple asynchronous AIS in syndromic patients. 
Exclusion criteria included:  
i) Previous intracranial radiotherapy;  
ii) Underlying conditions known to be risk factors for stroke (such as leukemia, 
cardiac, and other hematologic disorders);  
iii) Post-infective stroke with or without focal cerebral arteriopathy (such as post-
varicella angiopathy);  
iv) Post-traumatic arterial dissection in patients with no sign of collagen disease. 
Moreover, patients with Moyamoya disease were excluded since already included in another 
research project of our Institution. (Raso A, 2016) 
 
The DNA of all the eligible patients has been stored in the a DNA repository dedicated to 
pediatric stroke in the Medical Genetic laboratory of the Giannina Gaslini Institute. 
All patients underwent extensive hematological evaluation, to rule out major thrombophilia and 
sickle cell anemia, and cardiac evaluation with ECG and echocardiography (transthoracic 
and/or transesophageal), to exclude congenital and acquired heart diseases. Due to their high 
frequency in the normal population, patent foramen ovale and minor thrombophilia were not 
considered exclusion criteria for the genetic study. 
Array-CGH analysis was performed in selected cases when a syndromic condition caused by 
copy number variations was suspected. 
 
Clinical and radiological data collection 
Data of eligible patients were collected from paper and/or electronic medical records. Clinical 
data revision focused particularly on age and signs/symptoms at onset and clinical features at 
the age at genetic analysis. 
Brain MR studies were acquired using 3T or 1.5T MRI systems. Imaging protocols varied but 
always included axial T1, T2 and FLAIR images, diffusion-weighted imaging (DWI), 
susceptibility-weighted imaging (SWI), and intracranial MR angiography (MRA). Three-
experienced pediatric neuroradiologist (MS; DT; AR) reviewed neuroradiological images. 
Evaluation of MRIs included the presence and localization of AIS, cerebral and/or multi-
system arteriopathy, vessel and parenchymal calcifications, as well as additional brain 
anomalies.  
 
 Genetic Analysis 
DNA was extracted from blood samples by using the kit QIAamp DNA blood (Qiagen), 
purified with Amicon® Ultra-0.5 Centrifugal Filter Devices and quantified with NanoDrop 
2000. Patients were analyzed by the NGS approach using a customized gene panel designed 
through the Ion AmpliSeq designer software (http://www.ampliseq.com/browse.action) and 
containing 15 known genes, namely ABCC6, ACTA2, ATP7A, CBS, CECR1, CLO4A1, ELN, 










Figure 2. Main pathogenic mechanism of the 15 genes included in the NGS panel 
 
For each of the 15 genes Table 2 reports OMIM numbers, corresponding phenotypes, and their 
mode of inheritance, as well as GenBank ID, number of exons, and number of base pairs in the 
input target and in the designed panel, whose difference corresponds to missed target base pairs 
and amounts to a total of 1438bp. Therefore, the experimental design represents 98.30% of the 
input target. Sanger sequencing covered missed regions in suspected genes. Libraries 
preparation and successive DNA sequencing on the Ion Torrent Personal Genome Machine 
PGM
TM
 (ThermoFisher), were carried out according to ThermoFisher protocols.  
Once the whole target was captured by means of 441 multiplex amplification reactions, 
subdivided into two PCR pools (223+218 amplicons), not all the amplicons could be amplified 
with the same efficiency. Those resulted with a coverage less than 10X were analyzed through 
Sanger sequencing. Overall, the mean coverage of the whole panel among the 38 samples was 
356.61X (Table 2).  
 



















31 100 10975 264800: Pseudoxanthoma elasticum 
177850: Pseudoxanthoma elasticum, forme 
fruste 
ACTA2 102620 




8 100 2572 
614042: Moyamoya disease  
613834: Multisystemic smooth muscle 
dysfunction syndrome 
ATP7A 300011 




22 100 8051 
304150: Occipital horn syndrome 
300489: Spinal muscular atrophy, distal, X-
linked  
CBS 613381 
236200: Homocystinuria, B6-responsive and 
nonresponsive types AR 
NM_ 
001178008.2 
15 100 4822 
236200 Thrombosis, hyperhomocysteinemic 
CECR1 607575 




9 100 3985 615688: Polyarteritis nodosa, childhood-
onset 
COL4A1 120130 




52 100 15586 
611773: Angiopathy, hereditary, with 
nephropathy, aneurysms, and muscle cramps  
607595: Brain small vessel disease with or 
without ocular anomalies 
175780: Porencephaly  
614519: Hemorrhage, intracerebral, 
susceptibility to 
ELN 130160 




34 100 9401 
185500: Supravalvar aortic stenosis  
GLA 300644 




7 100 2151 
301500: Fabry disease, cardiac variant 
HTRA1 602194 600142: CARASIL syndrome AR 
NM_ 
002775.4 
9 94,98 3098 
  
616779: Cerebral arteriopathy, autosomal 
dominant, with subcortical infarcts and 
leukoencephalopathy, type 2 
     
610149: Macular degeneration, age-related,  
610149: Macular degeneration, age-related, 
neovascular type 
JAG1 601920 




26 99,82 8451 
187500: Tetralogy of Fallot 
NF1 613113 




58 99,04 20291 
162210: Neurofibromatosis, familial spinal 
162200: Neurofibromatosis, type 1 
601321: Neurofibromatosis-Noonan 
syndrome 
193520: Watson syndrome 
NOTCH3 600276 




33 83,99 11461 125310: Cerebral arteriopathy with 
subcortical infarcts and leukoencephalopathy  
130720: Lateral meningocele syndrome 
PCNT 605925 
210720: Microcephalic osteodysplastic 




47 99,37 19084 
SAMHD1 606754 




16 100 4955 
612952: Aicardi-Goutieres syndrome  
SLC2A10 606145 208050: Arterial tortuosity syndrome AR 
NM_030777.
3 
5 98,09 2747 
 
Bioinformatics analysis 
FastQ data were analyzed by the Ion Reporter 5.0. The total variants were filtered based on the 
frequency in the general population reported in the databases 1000 Genomes 
(http://www.internationalgenome.org) and Exome Aggregation Consortium (ExAC; 
http://exac.broadinstitute.org/). Variants were assessed by the Ion ReporterTM Software 5.0 
and a custom pipeline was additionally optimized to filter in significant variants. In particular, 
variants were selected based on their frequency in the general population (lower than 5% or 
unreported), for their impact on the encoded protein (missense, stop loss and stop gain, 
frameshift, and splicing variants at ±2bp from the exon ends), and for functional prediction (in 
silico analysis through online softwares, i.e. http://www.varsome.org) and/or previous 
pathogenicity classification (http://ww.clinvar.org). Variants thus selected were validate by 
standard Sanger sequencingin case they were never reported or reported as potentially 
damaging / damaging, their segregation was successively checked in parents, when available, 
and, finally, they were assessed on the basis of the clinical phenotype of probands. 
To confirm the presence of the selected variants, primers were designed with Primer3Plus 
(https://primer3plus.com/) and aPCR protocol was set up for each variant. PCR products were 
purified by ExoSAP-OT (GE Healthcare) and directly sequenced by using Big Dye V.1.1 
through a ABI3130 automated sequencer (Applied Biosystems, Foster City, California, USA).  
RESULTS  
Patients 
Of the 172 patients included in the biobank (Table 3) thirty-eight subjects (23 males and 15 
females) were considered eligible, based on the inclusion and exclusion criteria described 
above.  
Table 3. Demographic features of patient in Gaslini Stroke Biobank. 
 Total M (%) F (%) Age
*
 (SD) 
Total patients 172 102 (59,3) 68 (39,53) 6,95 (10,6) 
Total stroke patients 165 100 (60,61) 65 (39,39) 6,87 (10,77) 
Unconfirmed diagnosis 7 4 (57,14) 3 (42,86)  
Total Perinatal 83 51 (61,45) 32 (38,55) 2,54 (2,84) 
Perinatal 43 31 (72,09) 12 (27,91) 2,27 (3,17) 
Presumed perinatal 27 12 (44,44) 15 (55,56) 3,58 (2,21) 
Fetal 13 8 (61,54) 5 (38,46) 1,28 (2,24) 
Pediatric 75 47 (62,67) 28 (37,33) 7,64 (5,08) 
Adult 7 2 (28,57) 5 (71,43) 50 (17,42) 
* Age of the subject at the time of blood sampling for molecular study by NGS 
Eleven out of these 38 (28.9%) had a perinatal AIS onset while all the others were pediatric 
AIS. The mean age of at onset was 6.5 years (range: 0.2-12.5) in infantile cases while 7.1 
month (range 0.2-14 month) was the mean age at onset in perinatal/presumed perinatal cases. 
Hemiparesis was the most common neurological symptom at onset in patients with both 
pediatric and perinatal stroke (55.6% and 45.4% of cases respectively), followed by seizures in 
either groups (33.3% and 36.3% of cases respectively). While headache, visual loss and speech 
disorders were quite common symptoms at onset also in our pediatric patients (14.8%, 14.8%, 
and 11.1%, respectively), they were never reported as symptoms at onset in our cohort of 
perinatal stroke. Two patients with pediatric stroke presented an episode of inconsolable crying 
at the onset, in both cases associated with other focal neurologic symptoms. 
Two patients (1 with perinatal stroke and one with pediatric stroke) died, 1.1 year and 4 months 
after the first ischemic event, respectively. 
The mean age at molecular genetic analysis (NGS) was 6.5 years (range: 1 month to - 16.5 
years).  
Of the 27 pediatric patients, 11 subjects (40.7%) had a multisystem vascular involvement: 7 of 
those (25.9%) had persistent hypertension, moderate to severe, due to nephrovascular 
involvement; 6 patients (22.2%) had cutaneous vascular involvement (from intermittent forms 
of livedo reticularis to severe cutis marmorata). Surprisingly, none of them presented vascular 
retinal involvement, to date. However, in patients with genetic diagnosis confirmed through the 
NGS panel, an eye screening program has been started, aimed at identifying early eyes 
involvement. 
To date, only one of the patients diagnosed with perinatal or presumed perinatal stroke (patient 
#33)  has presented a multisystem vascular involvement, specifically, corneal haemorrhages 
and hypertension, probably of nephrovascular origin. 
Three patients, with pediatric stroke, had associated suspicious characteristics for an underlying 
immunological disease (severe recurrent infections, generalized lymphadenopathy and / or 
chronic systemic inflammatory condition). None of these was genetically diagnosed with the 
NGS panel. 
Neuroradiology 
As regards the neuroradiological features of the selected case, 23/38 (60.52%) patients had 
multiple AISs (14/23 with negative NGS and 10/15 with positive NGS), 5/38 (13.15%) had 
single AIS (2/23 with negative NCG and 3/15 with positive NGS), 7/38 (18.42%) patients had 
porencephalic cavities (4/23 with negative NGS and 3/15 with positive NGS; one patient had 
also multiple AHS), and 3/38 (7.89%) patients had only an arteriopathy (all with negative 
NGS). Three patients out of 38 (7.89%) had also associated AHSs (2/23 with negative NGS 
and 1/15 with positive NGS). Calcifications were present in 6 out of 38 patients (15.78%).  
Of the 24 multiple AISs, 17 (70.8%) cases were asynchronous (7/10 with positive NGS and 
10/14 with negative NGS) and 3 (12.5%) cases were synchronous (2/14 with negative NGS and 
1/10 with positive NGS). In 4/24 cases (16.6%) it was not possible to establish if the AIS were 
synchronous or asynchronous, since they were all detected in the chronic phase (2/14 with 
negative NGS and 2/10 with positive NGS). 
Beside the presence of AIS, additional MRI abnormalities were observed in 9 out of 38 subjects 
(32.14%). Four out of 38 patients (10.52%) showed white matter lesions (multifocal or diffuse), 
while the other 4/38 (10.52%) showed a Chiari I anomaly. One patient had multisutural 
craniosynostoses. A moyamoya-like arteriopathy was noted in 6/38 (15.78%) cases (1/15 with 




Cytogenetic analysis and other genetic analysis  
Cytogenetic analysis has been performed in patient with associated abnormalities (dysmorphic 
features, malformation in another organ system) or with psychomotor delay before the first 
stroke or when cognitive delay was unlikely justified by the location or extent of the ischemic 
lesion.  
Karyotype has been performed in nine patients (23.7%); only one of those, patient  #28, had 
abnormalities (45 X0/47 XXY//46 XY), probably not related to the clinical phenotype. 
Array comparative genomic hybridization (aCGH) has been performed in six patients (15.8%); 
two of those had structural aberrations.  
In patient #22 has been identified a microduplication  (12q24; 32q24.33);  inherited from the 
healthy mother.  
In patient  #1 (Figure 3) have been found two duplication 12p13.31p12.3 inherited from the 
mother (with a history of stroke at a young age) and 11p14.2p14.1 inherited from the father 
(suffering from chronic pyelonephritis, secondary to urinary tract malformation). Both genetic 
rearrangements are also identified in the eldest sister. in the large region of the chromosome 12 
is included GRIN2B, that could explain the mental retardation of the child and of the sister. 
Other genes (APOLD1 and ORL1), also contained in the same region, could predispose to 
thrombotic events; however, the role can not be defined precisely as that the older sister has 
never presented similar events. 
 
 
Figure 3. Neuroimaging of patient #1. A) Brain CT with 3D reconstruction. B, C) 
Brain MRI with multiple unilateral synchronous AISs in left MCA perforating arteries 
territory, without arteriopathy; multifocal bilateral WM lesions and ventricular 
dilatation 
 
In two patients (#21 and #17), with suspect of Williams syndrome, has been performed FISH 
analysis in order to identify the submicroscopic deletion, at 7q11.23,  
responsible for allelic loss of elastin (ELN). Both patients results negative to the FISH analysis. 
The search of the main molecular thrombophilias (Factor II G20210A  and Factor V Leiden) 
was performed in 31 patients (81.6%). In 2 patients, both with perinatal stroke, the presence of 
minor thrombophilia was detected (in the patient #15 a heterozygotic mutation G20210A of 
factor II and in the patient #29 a mutation in heterozygosity of factor V Leiden have been 
identified). Both mutations could have had a role as a co-risk factor in the genesis of the 
ischemic event. 
Patient #10, with clinical diagnosis of Sotos Syndrome, has a NSD1 de novo mutation in intronic 
splicing site (never described before). To date there are no data in the literature that report an 
association between Sotos syndrome and early strokes; therefore, this mutation was not 
considered an exclusion criterion for the NGS panel, hypothesizing a possible concausality of 
two distinct mutations. 
Patient #27 carried out, at another center, an NGS panel aimed at the study of collagenopathies 
(including COL3A1, COL5A1, COL1A2, FBN1, TGFBR1, TGFBR2, MYH11, SMAD3, 
FBN2, MYLK, NOTCH1, TGFB2); the molecular analysis showed in exon 40 of COL1A2 
gene the presence in heterozygosity of the sequence variation c.2465G> A, which results in the 
amino acid substitution p.Arg822His. This variant is not included in the databases available to 
date (i.e. ClinVar, HGMD) and is predicted of uncertain significance. Moreover, the same 
variant is inherited from the healthy mother. 
Patient #7 has previously performed the study of the RNF213 gene, known as related to the 
disease of moyamoya with autosomal dominant mode. The analysis shows the presence of a 
single mutation, whose segregation is being validated. The presence of a RNF213 mutation, has 
not been considered a criterion of exclusion from genetic analysis with NGS panel, not being 
able to justify the clinical phenotype of the patient. 
 
Genetic Analysis 
The mean sequencing coverage depth was 356.61X, with a mean number of variants called of 
144.13, and a mean of 4.49 number of variants filtered according to given criteria, namely to be 
investigated further. In total, 86 variants were identified, 66 of which were called only once 
while the other 20 were called repeatedly, from 2 to 20 times. Of those, 56 variants resulted 
with an allele frequency<0.05 and reasonable quality (p-value<0.01 and no distorted allelic 
ratio). Finally, among variants undergone Sanger sequencing validation, Table 3 reports only 
patients with carrying only validated (true positive) variants. Indeed, after validation and 
familial testing, no significant variant was left in 23 patients, that can therefore be considered 
as “genetically negative” for the conditions tested. Conversely, variants found in the 15 patients 
reported in Table 4 were taken into account as potentially accounting for their clinical 
phenotype and followed up with the assessment of their de novo/inherited nature, effect 
prediction through the online tools quoted in the previous Materials and Methods section, and 









Table 4. List of patients with validated variants. 
 
Clinical and genetic diagnosis 
Based on clinical, neuroradiological and laboratory findings, an etiological hypothesis was put 
forward in 17 patients, expecting mainly COL4A1 but also PCNT, ACTA2, CBS, ADA2 and 
ELN mutations, while the 20 others were classified as affected by an undetermined condition. 
NGS analysis provided results in 15 out of 38 patients (39.5%), leading to a definite etiological 
diagnosis in 4 of them showing pathogenic or likely pathogenic variants. Of the remaining 11 
cases, 6 subjects harbored variants of unknown significance while 5 patients had benign or 
likely benign variants. Due to predicted low impact (either benign, likely benign, or variants of 
unknown significance) and inconsistent clinical features, genetic inheritance, and/or 
neuroradiological patterns, these mutations were not further pursued (Tables 4 and 5). 
Ultimately, only 2 out of 17 patients with an already suspected diagnosis and 2 out of 21 
patients with an undetermined condition received a genetic diagnosis. Clinical, 
neuroradiological and histological data (whenever available) are detailed in Table 5 for the 15 
patients with positive NGS and in Table 6 for the remaining 23 patients. 
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Pathogenic or likely pathogenic mutations 
Among the 4 patients harboring P/LP mutations, three presented ABCC6 variants: one in 
compound heterozygosis (patient #17) and 2 in heterozygosis (patients #20 and #38). 
In particular, patient #17 (Figure 4), presenting at 2 years of age with an AIS associated with 
multidrug resistance hypertension and multisystemic arteriopathy, harbored two rare 
heterozygous ABCC6 mutations (c.2900G>A; p.Trp967* and c.4182_4182delG; 
p.Lys1394Asnfs*9), each transmitted from one parent. This allowed the diagnosis of 
pseudoxanthoma elasticum (PXE) before the manifestation of any skin or ocular signs, as we 
previously reported (Bertamino M, 2018).  
 
Figure 4. Neuroimaging of patient #17. Brain MRI (A, B), MRA (C) and Digital Angiography (D,E) 
with AIS in the left MCA territory, non-inflammatory MCA arteriopathy and bilateral segmental ICAs 
agenesis with carotid rete mirabile. Abdominal MRA (F) with evidence of a multisystem stenotizing 
arteriopathy (iliac arteries). 
 
The other two patients #38 (Figure 6) and #20 (Figure 7), respectively harboring heterozygous 
p.Arg391Gly and p.Glu699Asp mutations, presented with a similar clinico-radiological 
phenotype characterized by multiple asynchronous AISs due to multiple dissections, in the 
absence typical PXE features (skin and ocular) and/or collagenopathy signs. 
Finally, patient #3 (Figure 7) presented a de novo likely pathogenic c.2132G>A (p.Gly711Glu) 
mutation associated with a clinical and radiological picture suggestive for a Collagen IV- 
related disorder. He was born small for gestational age and experienced seizures in the second 
day of life. Afterwards, he presented a multidrug-resistant epilepsy associated with cataracts 
and intermittent marked increase plasmatic creatine kinase values (CK). 
 
 
Figure 5. Neuroimaging of patient #38. Brain MRI and MRA with multiple 
unilateral asynchronous AIS in the left PICA and PCA perforators associated 
with multiple stenosis of the V3 and P1/P3 segments due to multiple dissections 
 
 
Figure 6. Neuroimaging of patient #20. Brain CT, MRI and MRA with multiple 
bilateral asynchronous AIS in the left PCA and right PICA arteries, due to 
multiple asynchronous VA dissections 
 
 
Figure 7. Neuroimaging of patient #3. Brain MRI Multiple bilateral AHS, porencephaly and deep brain 
calcifications. 
 
Variants of unknown significance (VUS) 
Six patients presented variants of unknown significance in different genes. Three patients (#2, 
#10 and #15) harbored heterozygous VUS in PCNT, ATP7A and CECR1 genes, respectively, 
related to autosomal recessive disorders. Moreover, their clinical and radiological phenotype 
was not consistent with any of these conditions. 
Patient #2 and  #15 had a porencephalic cavity with deep calcifications, neuroradiological 
findings compatible with COL-IV related disorder; patient  #10 diagnosed with Sotos syndrome 
has been previously described. 
Patients #21 presenting with neonatal AIS and hypercalcemia with hypercalciuria harbored a 
NOTCH3 mutation not consistent with the clinical phenotype.  
Patients #22 was shown heterozygote for the ABCC6 p.Arg1064Trp but presented with a very 
severe phenotype characterized by intestinal malrotation, cutis marmorata and early onset and 
rapidly progressive multisystemic arteriopathy causing multiple AISs. Due to the severity and 
complexity of the clinico-radiological picture, this patient was addressed to whole exome 
sequencing (WES) analysis. 
Patient #16 harbored a p.Pro3Thr variant in COL4A1 inherited from the healthy father and 
showed a presumed perinatal AIS associated with nonspecific contralateral white matter 
lesions. 
 
Benign or likely benign variants 
NGS demonstrated benign or likely benign variants in CECR1, COL4A1, ABCC6, and CBS, in 
five patients. A single mutation in CECR1, related to an autosomal recessive disorder (ADA2 
deficiency), has been found in patient #12 and #14.  
Patient #12 had a non-inflammatory cerebrovascular involvement, moyamoya-like,  without 
other signs of systemic involvement. 
Patient #14 had early onset rapidly progressive multifocal cerebral and multisystemic 
arteriopathy, hesitated in the patient's death, a few months after the first stroke due to systemic 
malignant hypertension and multi organ failure. Due to the severity and complexity of the 
clinico-radiological picture, this patient was addressed to WES analysis. 
A single mutation in CBS, related to an autosomal recessive disorder, has been found in patient 
#25. This male subject had multiple bilateral AISs without vasculopathy. Anamnestic history 
revealed a suspected regulation of the immune system. Plasma homocysteine repeatedly 
normal. 
Patient #19 was found to carry two heterozygous ABCC6 variants, namely p.Ile742Val and 
p.Arg724Lys. This female patient, has a multifocal cerebral inflammatory arteriopathy with 
associated severe hepatosplenomegaly and generalized lymphadenopathy, corneal deposits, 
itiotic skin, joint retraction and arthritis, short stature, reduced HDL level. Due to the 
phenotypic complexity and the known consanguinity of the parents (second cousins), the 
patient was referred to WES analysis. 
Patient #6 presented with severe headaches with detection on brain MRI of multifocal and 
asynchronous cortical AISs. The patient was affected by hereditary spherocytosis and a 
moderate hyperhomocysteinemia. Both of these findings could be considered co-risk factors 
but were not sufficient to cause multiple AIS in childhood. On the other hand, neither the 
detected COL4A1 variant (p.Pro304Leu) was responsible of the clinico-radiological phenotype. 
 
Genetically unclassified patients  
Clinical and radiological features of those 23 patients resulted with negative NGS are reported 
in Table 6.  
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Six of the 23 negative patients (26.1%) were perinatal or presumed perinatal stroke. Four of 
those were considered eligible at the NGS panel, in the suspicion of a COL4A1-related disease. 
Patient #26 and patient #29 were included because of a porencephalic cavity associated with a 
strong family history of pediatric or perinatal stroke. Patient #31 was included in the study for 
the detection of a porencephalic cavity, associated with a diffuse leukoencephalopathy. Patient 
#33 has also been studied in the suspicion of COL4A1 mutation in the light of the brain-MRI 
with multiple asynchronous hemorrhagic stroke, associated with neonatal cataracts and retinal 
hemorrhages. Parallel to this investigation, the study of genes for familial hemorrhagic 
telangiectasia was started, in the light of multiple arteriovenous malformations (AVMs). 
Two patients (patient #36 and patient #28) were included in the suspicion of a PCNT related 
disorders; both present a highly suggestive clinical and neuroradiological phenotype for a 
microcephalic primordial dwarfism. It is also known that this phenotype can be explained by 
mutations other than PCNT, namely ATR, CDC6, CDT1, CENPJ, CEP152, CEP63, ORC1, 
ORC4, ORC6, RBBP8, RNU4ATAC . Both of these patients were addressed to further 
molecular diagnostic investigations, once a chromosomal aberration was excluded through 
cytogenetic analysis. 
Eight patients, 7 of those with pediatric stroke, had a multisystemic vasculopathy, 5 of those 
(patients #4, #7,  #27, #33 and #37) had associated hypertension, three had cutaneous 
involvement (patients #18,  #24 and #30), one (patient #33)  has retinal haemorrhages, has 
already mentioned. 
Three negative patients  (patients #9,  #13 and #27), had a non-inflammatory vasculopathy 
(cerebral with/without systemic involvement) and a marfanoid habitus. 
The patient #32 has a non-inflammatory cerebral vasculopathy associated with alterations of the 
green matter, similar to a syndrome of Leight, which, moreover, has been excluded in the proband. 
Given the peculiarity of the neuroradiological pattern, the patient was subsequently directed to 
WES. 
One of the remaining 7 patients had a perinatal stroke due to left internal carotid artery (ICA) 
dissection with family history of aortic dissection (patient #34); this patient was referred to the 
panel in the suspicion of a ACTA2-related disease. 
Two subjects (patient #8 and #35) had multiple asynchronous pediatric AISs without arteriopathy; 
the first of the two, female, had associated a congenital scoliosis due to cervico-dorsal vertebral 
malformations. 
Patient  #11 had a peculiar phenotype characterized by congenital hip dysplasia and 
laryngomalacia, she had seizures and hemiparesis, to which a Claude Bernard Horner syndrome 
was add, due to unilateral synchronous AISs in right middle cerebral artery (MCA) territory with 
moyamoya-like arteriopathy. 
Patient #23 had a bilateral non-inflammatory arteriopathy of the posterior circulation with 
associated bilateral multifocal white matter alterations; to date no signs of multisystem vascular 
involvement have occurred. 
Patient #5 had a pediatric onset of multiple asynchronous and rapidly progressive ischemic and 
hemorrhagic stroke in posterior circulation without arteriopathy. 
Lastly, the patient #1, previously genetically described in the chapter of cytogenetic investigations, 
has multiple unilateral synchronous AISs without arteriopathy, associated with multifocal bilateral 
white matter lesions, multi-sutural cranyosinostoses with ventricular dilatation and Chiari I 
anomaly. 
In patient #17 has successfully been defined following, the detection of two heterozygous 
ABCC6 mutations (c.2900G>A; p.Trp967* and c.4182_4182delG; p.Lys1394Asnfs*9), each 
transmitted from one parent. This has, allowed to diagnose pseudoxanthoma elasticum (PXE) 
before the manifestation of any skin sign, as already reported (Bertamino M, 2018).  Additional 
mutations were detected at the ABCC6 gene: patient #19 was found to carry two heterozygous 
ABBC6 variants, namely p.Ile742Val and p.Arg724Lys, while patients #22, #38, and #20 were 
shown heterozygotes for the ABCC6 p.Arg1064Trp, p.Arg391Gly, and p.Glu699Asp 
mutations, respectively, the two latter ones transmitted by asymptomatic fathers (Table 2). 
Interestingly, patient #20 carries a pathogenic mutation that, though expected to associate with 
no PXE, may have contributed to his phenotype. 
Mutations of the ATP7A, CECR1, NOTCH3, PCNT, and CBS genes were also detected. 
However due to the predicted low impact effect and to the inconsistent clinical features and 
neuroradiological patterns, these mutations were not further pursued (Tables 5 and 6). 
 
Genetically unclassified patients 
Clinical and radiological features of those 23 patients resulted with negative NGS are reported 
in Table 4.  Qui va descritta secondo me la tabella 4, riportando il tipo di info che vi si possono 
trovare e eventuale ricorrenza tra I pazienti di sintomi rari o particolari o altra considerazione 
che aiuti a inquadrare questa casistica negative … I commenti nella discussione 
Six of the 23 negative patients (26.1%) were perinatal or presumed perinatal stroke. Four of 
those were considered eligible at the NGS panel, in the suspicion of a COL4A1-related disease. 
Patient #26 and patient #29 were included because of a porencephalic cavity associated with a 
strong family history of pediatric or perinatal stroke. Patient #31 was included in the study for 
the detection of a porencephalic cavity, associated with a diffuse leukoencephalopathy. Patient 
#33 has also been studied in the suspicion of COL4A1 mutation in the light of the brain-MRI 
with multiple asynchronous hemorrhagic stroke, associated with neonatal cataracts and retinal 
hemorrhages. Parallel to this investigation, the study of genes for familial hemorrhagic 
telangiectasia was started, in the light of multiple arteriovenous malformations (AVMs). 
Two patients (patient #36 and patient #28) were included in the suspicion of a PCNT related 
disorders; both present a highly suggestive clinical and neuroradiological phenotype for a 
microcephalic primordial dwarfism. It is also known that this phenotype can be explained by 
mutations other than PCNT (included in our NGS panel), namely ATR, CDC6, CDT1, CENPJ, 
CEP152, CEP63, ORC1, ORC4, ORC6, RBBP8, RNU4ATAC . Both of these patients were 
addressed to further molecular diagnostic investigations, once a chromosomal aberration was 
excluded through cytogenetic analysis. 
Eight patients, 7 of those with pediatric stroke, had a multisystemic vasculopathy, 5 of those 
(patients #4, #7,  #27, #33 and #37) had associated hypertension, three had cutaneous 
involvement (patients #18,  #24 and #30), one (patient #33)  has retinal haemorrhages, has 
already mentioned. 
Three negative patients  (patients #9,  #13 and #27),had a non-inflammatory vasculopathy 
(cerebral with/without systemic involvement) and a marfanoid habitus. 
The patient #32 has a non-inflammatory cerebral vasculopathy associated with alterations of 
the green matter, similar to a syndrome of Leigh, which, moreover, has been excluded in the 
proband. Given the peculiarity of the neuroradiological pattern, the patient was subsequently 
directed to WES. 
 
WES IN PEDIATRIC STROKE 
Massive sequencing (WES) of selected cases, arisen negative at the above described NGS 
panel, has been performed to identify one or more new genes involved in the pathogenesis of 
pediatric stroke and to study variants segregation within families.  
The whole trios (proband plus parents), or the enlarged nuclear family if more subjects are 
presenting a compatible disease phenotype, has been included in the WES analysis.  
A pathway analysis and other both in silico and experimental approaches, useful to identify 
biological mechanisms affected in the disorder(s) and to confirm the gene(s) involvement, have 
been scheduled.  
WES in patients affected with stroke, with no mutation(s) accounting for their phenotype, has 
been carried out in-house, by taking advantage of the Ion Proton TM (ThermoFisher) platform, 
available in our Institute.  
To date, we have already performed WES analysis in four cases. 
 
Patient #22  
First WES has been performed in Patient #22 and her healthy non-consanguineous parents, 
finding compound heterozygous mutations, confirmed by Sanger sequencing, in the ABCG2 
gene (Rusmini et al, unpublished).  
Patient #22 had cutis marmorata at birth, macrocrania and mild facial dysmorphism, a bilateral 
syndactyly, intestinal malrotation and a diagnosis of long QT syndrome. First cerebral stroke 
was referred at the age of 5 months, with subsequent severe progression of cerebral 
vasculopathy. From the age of 5 years, she had a severe nephrovascular arterial hypertension in 
the context of a multisystem vasculopathy, definable as fibromuscular dysplasia, as confirmed 
by arterial biopsy. 
The CGH Array of patient #22 showed micro-duplication of the long arm of chromosome 12 
(12q24; 32q24.33); this rearrangement was inherited from the healthy mother. 
The mutated ABCG2 gene is a member of the ATP-binding cassette (ABC) transporter 
superfamily that actively export drugs and toxins from the cells, to limit adverse effects of 
xenotoxins 13. These variants, annotated for the transcript ENST00000237612, are p.I456V (no 
rs number available) and p.M514K (rs752530602). The two mutations may be pathogenic as  
i) p.I456V has never been described before and  
ii) p.M514K has been reported only in 1/121190 alleles in the ExAC database. In addition, 
both variants are predicted to have a high CADD (Combined Annotation-Dependent 
Depletion, http://cadd.gs.washington.edu/) score (>13), recently regarded as a reliable 
index of variant pathogenicity.  
Despite the absence of published data regarding the involvement of this gene in arteriopathies, 
a pathway search of ABCG2 through the PathwayNet software (http://pathwaynet. 
princeton.edu/) showed a link with the HIF1 (Hypoxia-inducible factor-1) -alpha transcription 
factor network, consistent with the role of low oxygen levels in stimulating the production of 
angiogenic factors. Under conditions of normoxia, HIF-1 alpha is cytoplasmic and is rapidly 
degraded by the ubiquitin proteosome system. In mammalian cells, reduced oxygen levels, as it 
occurs in specific districts during embryogenesis, permit the accumulation of HIF-1 alpha 
protein in the cytoplasm. Subsequently, it translocates to the nucleus, engages HIF-1 beta, and 
forms the HIF-1 complex that initiates VEGF transcription and mRNA stabilization.  
Functional studies are nearing completion to confirm the role of the pathogenic mutation in the 
genesis of the phenotype of the subject. 
 
Patient #14  
Second WES has been performed in Patient #14 and her healthy parents; parental 
consanguinity is suspected, having found a homozygous mutation of a gene whose product 
functions as a guanine nucleotide exchange factor for a small GTPase protein regulating 
signaling pathways downstream of integrins and growth factor receptors.  
Patient #14 was born at term of a normal pregnancy; auxological parameters at birth were 
within normal limits. Absent dysmorphism. Well-being and normal psychomotor development 
up to 10 months when he presented the first stroke, with evidence of a multifocal stenosing 
vasculopathy (involving at first aorta and medium-sized intracranial arteries). At the age of 11 
month was detected a severe hypertension, multi drug resistant, with bilateral renal artery 
rapidly progressive narrowing. Stenosing vascular disease it has also spread to other districts 
such as the supra aortic trunks, iliac and femoral artery. She experienced multiple arterial 
ischemic stroke despite aggressive anticoagulant and steroid treatment and death after 3 month 
of hospitalization due to cardiac impairment and multi organ failures.  
The mutation detected in Patient #14 appears to play a role in the reorganization of the actin 
cytoskeleton in endothelial cells. 
Further functional studies are underway to confirm the pathogenicity of the mutations found 
and the role in the genesis of the phenotype of the subject. 
 
Patient #4  
Third WES has been performed in Patient #4, her younger sister and their healthy related 
parents. Both sisters are affected by a multifocal stenosing cerebral vasculopathy; the patient #4 
experienced multiple arterial ischemic stroke while the younger sister is currently 
asymptomatic. 
Patient #4 has an early onset systemic hypertension. A skin biopsy was performed with the 
finding of a non-specific collagen type-I deficiency.  
To date, no other signs or symptoms of systemic vascular involvement in the sister are present. 
In the aforementioned family the WES study has already been done, the analysis is underway, 
and some candidate genes are being highlighted. 
Patient #4 and her sister were sent to our attention from another center. A multidisciplinary 
evaluation is planned for the two patients at our center, for an accurate clinical evaluation and 
an advanced neuroradiological study. These data will be useful in the interpretation of the 
results of the WES and to better address the functional studies. 
 
Patient #32 
The last WES analysis, carried out on patient #32 and his non-consanguineous parents, is still 
ongoing.  
The father of the proband is healthy while the mother has a malignant liver tumor. Both parents 
and the older brother do not show signs or symptoms of vascular or cerebrovascular disease. 
Patient #32 was born at term of a normal pregnancy; auxological parameters at birth were 
within normal limits. Absent dysmorphism. Well-being and normal psychomotor development. 
At the age of 4 months he experienced epileptic seizures in apyrexia; brain MRI revealed an 
early onset moyamoya-like cerebrovasculopathy with a very peculiar, slowly progressive, 
alterations of the deep gray substance. Such alterations had led to think of a Leigh syndrome, 
but the metabolic profiling and muscle biopsy excluded this hypothesis. 
DISCUSSION 
The complexity of the different clinical phenotypes belonging to the Arterial Ischemic Stroke 
(AIS) spectrum is not fully accounted for by the genes and other risk factors identified so far. In 
particular, pediatric AIS differs from adult AIS in many respects, including the nature of the 
main risk factors. Indeed, while Mendelian genetic factors contribute more likely to the 
infantile onset, environmental and genetic predisposing risk factors may play a major role in 
adult stroke. Therefore, very different genetic approaches are required in the two age groups. 
It is generally thought that monogenic strokes have a unique phenotypic pattern and that 
individual mutations predispose to specific stroke subtypes [Markus HS]. However, at least in 
pediatric forms, none of the clinical or neuroradiological findings is specific of a given 
arteriopathy subtype, and the genotype-phenotype correlation apparently expand to include 
more genes and wider clinical spectra [Dlamini N]. This implies that single-gene testing cannot 
be informative enough to be used especially in a diagnostic setting, besides being too expensive 
and time-consuming. With reasonable sequencing costs and improved bioinformatics 
approaches for data analysis, NGS is increasingly used in the diagnostic workup of many 
pediatric diseases [Dlamini N, Abou Tayoun AN, Tonduti D]. In this study, we applied a 
targeted NGS technology to the parallel screening of multiple genes in children with idiopathic 
AIS. To avoid including a very heterogeneous set of pediatric AIS patients, we decided to focus 
on a precise subset based on definite inclusion criteria and with a likely genetic 
etiopathogenesis (i.e., familiarity, multiple lesions, multisystem vascular involvement, no post-
infective or post-traumatic events). To this end, patients were selected after a careful 
multidisciplinary approach, including specialized clinical evaluations (physiatric, infant 
neuropsychiatric, psychological, cardiological, genetic), and instrumental examinations, such as 
electrophysiological studies and advanced neuroimaging. Despite this relatively restrictive 
approach, the study population remained quite heterogeneous, reflecting the complexity and 
diversity of the associated risk factors in children with AIS compared to the adult population. In 
addition, we also decided to restricte the NGS based panel to a limited number of genes known 
to be responsible of simple monogenic disorders sharing stroke as one of their most common 
and early manifestation, including genes involved in vascular development, homoeostasis, and 
response to environmental factors in the pathogenesis of pediatric AIS and cerebral 
arteriopathies. [Munot P, McCrea N] 
The present exploratory study has demonstrated the feasibility of a clinical and genetic 
integration by targeted NGS in the clinical workflow of pediatric and perinatal AIS of unknown 
etiology. In our cohort, the targeted 15-gene panel has increased the diagnostic rate of 
monogenic conditions associated with AIS to 10.5%, with a very relevant impact on the clinical 
management of patients thus diagnosed.  
In particular, among positive cases we found three patients, either heterozygotes (two) or 
compound heterozygote (one) for ABCC6 mutations, while one patient harbored a COL4A1 
variant. Mutations in ABCC6 are responsible for pseudoxanthoma elasticum (PXE), a rare 
autosomal recessive disorder characterized by the accumulation of mineralized and/or 
fragmented elastic fibers in the skin, eyes, vascular walls, and gastrointestinal system. Patients 
with PXE commonly present with skin papules and/or retinal angioid streaks, usually around 
the second decade of life, while vascular lesions and cerebrovascular complications are rarer 
but may cause severe neurologic impairment [Germain DP]. Remarkably, the patient with 
compound heterozygous ABCC6 mutations presented an atypical and severe phenotype 
characterized by early AIS associated with multi-system arteriopathy and a compensating 
arterial network, called carotid rete mirabile, as previously reported [Bertamino M]. In this 
case, NGS-based gene panel testing allowed early PXE diagnosis even in the absence of typical 
skin and ocular manifestations, thus leading to a timely genetic counseling, targeted therapeutic 
and prevention measures. Conversely, the two other patients were heterozygotes for two 
different missense ABCC6 mutations and presented with multiple spontaneous cervical artery 
dissections (sCAD) without typical skin or ocular PXE features. Of note, recent genetic studies 
in young adults with sCAD have shown the presence of small deletions encompassing ABCC6 
[Morcher M], while heterozygous ABCC6 variants have been described in patients with aortic 
dissections [Schulz V]. Moreover, histology studies in subjects with sCAD have demonstrated 
aberrations restricted to the elastic fiber system in the reticular dermis [Uhlig P] resembling our 
observation of symptomatic heterozygotes of recessive PXE, consistent with autosomal 
dominant transmission of forme fruste PXE (OMIM#177850), already reported with reduced 
penetrance [Struk B, vanSoest S].  
Remarkably, in none of the cases harboring ABCC6 variants was the diagnosis suspected 
before genetic testing. Conversely, among the eight patients originally suspected for a collagen 
IV-related disease, only one received a genetic confirmation. This discrepancy may be related 
to the fact that the COL4A2 gene, encoding the alpha-2 chain of type IV collagen, was not 
included in the NGS panel, thus reducing the diagnostic yield of the study. The clinical 
spectrum of COL4A1 and COL4A2-related disorders is overlapping and includes small-vessel 
brain disease variably associated with eye defects (retinal arterial tortuosity, Axenfeld-Rieger 
anomaly, cataract) and systemic findings (kidney involvement, muscle cramps, cerebral 
aneurysms, Raynaud phenomenon, cardiac arrhythmia, and hemolytic anemia). On imaging, 
small-vessel brain disease causes diffuse periventricular leukoencephalopathy, lacunar infarcts, 
microhemorrhage, dilated perivascular spaces, and deep intracerebral hemorrhages. Moreover, 
porencephaly and transmantle lesions, causing hydranencephaly or schizencephaly, have also 
been reported. 
The majority of patients in the present study remained without a genetic diagnosis, including 
several patients with cerebral or multisystem arteriopathies. In some instances, this might be 
explained by the high variability and complexity of the clinical-radiological phenotype of these 
patients, often including multisystemic involvement and additional syndromic or inflammatory 
features. These patients represent very good candidates to search for new genes through Whole 
Exome Sequencing (WES) [Bamshad MJ], and a large specific gene panel for in silico analysis 
has already been designed and proposed [Sawyer SL].  
The present study has several limitations. First, idiopathic AIS is a rare condition, accounting 
for about 10% of all pediatric strokes; thus, the small sample size did not allow the creation of 
homogeneous and reasonably large subgroups based on clinical and neuroradiological 
phenotypes. A tertiary pediatric centers network would allow to collect a larger amount of 
cases. Secondly, the number of genes included in the panel was quite limited compared to the 
wide phenotypic heterogeneity of the patient series. A larger and more comprehensive gene 
panel might improve the molecular diagnosis and therefore the clinical management of 
pediatric and perinatal stroke (including the hemorrhagic forms) [McCrea N].    
In conclusion, the present pilot study has demonstrated a modest but satisfactory increased 
diagnostic rate of monogenic conditions associated with pediatric AIS, widening the 
phenotypic spectrum of ABCC6-related disorders and improving the genetic counseling and 
clinical management of positive patients. We plan to improve the present multidisciplinary and 
innovative approach to pediatric idiopathic AIS by updating the NGS-based gene panels and 
applying WES as a second-line approach to selected negative patients. This might pave the way 
for future larger multicentric studies, thus shedding more light on the complex 
pathophysiology/genetic bases of this rare condition. 
 
CONCLUSION 
Identification of a genetic basis for pediatric and perinatal stroke through NGS will strongly 
contribute to the full knowledge of perinatal and pediatric stroke. 
This will improve the management of the patients, enabling identification of effective therapies, 
targeted rehabilitation and, ideally, prevention of the disease.  
The use of NGS technologies represents the future of the genetic diagnosis and could become 
the most suitable and feasible diagnostic option also in pediatric stroke, after the exclusion of 
more common etiology. Presently, gene panel testing is the favored choice for genetic-stroke 
diagnosis due to the lower cost and higher coverage of the technology. However, as the price 
for WES and WGS continues to decrease, they will soon be fully integrated into the diagnostic 
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